- In May 2025, IQVIA, a global leader in clinical research and data analytics, announced the launch of its enhanced pharmacovigilance platform designed to streamline adverse event reporting and improve drug safety monitoring worldwide. The platform leverages advanced analytics and real-time data integration to provide faster insights, enabling healthcare providers and pharmaceutical companies to make informed safety decisions. This innovation underscores IQVIA’s commitment to advancing drug safety and regulatory compliance
- In April 2025, Cognizant expanded its Drug Safety Solutions portfolio by integrating AI-driven automation tools to enhance case processing efficiency and accuracy. The company reported significant reductions in manual data entry errors and faster turnaround times for safety reports. This strategic development reflects Cognizant’s focus on digital transformation in pharmacovigilance services
- In March 2025, Parexel International Corporation partnered with a leading biotech firm to deploy its cloud-based pharmacovigilance system across multiple clinical trial sites globally. This initiative aims to unify safety data collection and reporting, ensuring consistent regulatory compliance and improved patient safety across trials. The collaboration highlights Parexel’s role in facilitating innovative drug safety management solutions
- In February 2025, ArisGlobal launched its latest version of the LifeSphere Drug Safety platform, featuring enhanced risk management and signal detection capabilities powered by machine learning. This update offers pharmaceutical companies greater precision in monitoring drug safety signals and supports faster regulatory submissions, reinforcing ArisGlobal’s position as a pioneer in pharmacovigilance technology
- In January 2025, Labcorp Drug Development announced the integration of real-world evidence data into its drug safety monitoring services to better assess post-market safety profiles. The company emphasized that this holistic approach enhances pharmacovigilance outcomes by combining clinical trial data with patient data from diverse healthcare settings, promoting safer drug use globally
